The therapeutic benefits of psychedelic medicines may not require the psychoactive effects.
The early results of a COMPASS Pathways clinical trial quell some concerns related to the safety of psychedelic therapy for individuals with bipolar disorder.
The author recalls conversations with the spiritual leader and psychedelic pioneer about his Jewish roots.
Be the nerdiest person at your holiday parties this year by dispelling one of the most persistent psychedelic history myths!
As psychedelic-assisted therapies near FDA approval, questions remain about cost, who’s paying, and how much it saves patients and insurers in the long run.
The results of the company’s Phase 2b trial raise concerns around safety, efficacy, and money, suggesting key questions to be addressed in Phase 3.
UNIFY founder Adil Kassam discusses how technology coupled with global group meditation can facilitate synchronized transformational experiences among millions of people.
The medicalization of psychedelics may be changing people’s minds, but can these developments result in deeper changes in how we view or access medicine?
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions.